Ad
related to: best central heating inhibitors for cancer
Search results
Results from the WOW.Com Content Network
Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. [4] Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5] Inappropriate activation of the pathway has been shown to occur in many cancers. [5]
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR: Medullary thyroid cancer. Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon). 2.3 mTOR inhibitors: Everolimus: PO: mTOR inhibitor.
An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein.Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. [2]
Fruquintinib, sold under the brand name Fruzaqla, is an anti-cancer medication used for the treatment of colorectal cancer. [6] Fruquintinib is a kinase inhibitor. [6] It is taken by mouth. [6] The most common adverse reactions include hypertension, palmar-plantar erythrodysesthesia, proteinuria, dysphonia, abdominal pain, diarrhea, and ...
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. [ 1 ] [ 5 ] [ 7 ] It is an inhibitor of tropomyosin kinase receptors TrkA , TrkB , and TrkC . [ 8 ] [ 9 ] [ 10 ] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. [1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. [2] It has been given conditional approval for these indication in China. [3]
Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell. [3] [8] Nilotinib was approved for medical use in the United States in 2007. [3] [8] It is on the World Health Organization's List of Essential Medicines. [9] It is approved as a generic medication. [10]
Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC 50 0.8 nM), HER-2 (IC 50 19 nM) and ErbB-4 (IC 50 7 nM). [1] [2] By 2015, Pfizer had discontinued development of the drug. [3]
Ad
related to: best central heating inhibitors for cancer